Alibaba
BABA
Broadcom
AVGO
Tesla
TSLA
4
Netflix
NFLX
5
NVIDIA
NVDA
US Stock MarketDetailed Quotes
ALNY Alnylam Pharmaceuticals
- 239.405
- +6.335+2.72%
Trading Mar 11 11:47 ET
30.99BMarket Cap-109.82P/E (TTM)
239.550High230.850Low155.48KVolume230.850Open233.070Pre Close36.57MTurnover0.13%Turnover RatioLossP/E (Static)129.46MShares304.39052wk High462.17P/B29.80BFloat Cap141.97552wk Low--Dividend TTM124.46MShs Float304.390Historical High--Div YieldTTM3.73%Amplitude3.650Historical Low235.202Avg Price1Lot Size
About Alnylam Pharmaceuticals Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Company Profile
SymbolALNY
Company NameAlnylam Pharmaceuticals
Listing DateMay 27, 2004
Issue Price6.00
Founded2002
CEODr. Yvonne L Greenstreet, MB.Ch.B.
MarketNASDAQ
Employees2230
Fiscal Year Ends12-31
Address675 West Kendall Street,Henri A. Termeer Square
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-551-8200
Websitehttp://www.alnylam.com
Company Executives
- Name
- Position
- Salary
- Dr. Yvonne L Greenstreet, MB.Ch.B.
- Director and Chief Executive Officer
- 8.90M
- Dr. Pushkal P. Garg, M.D.
- Chief Medical Officer and Executive Vice President, Development and Medical Affairs
- 3.23M
- Tolga Tanguler
- Chief Commercial Officer
- 2.87M
- Kevin Joseph Fitzgerald, PhD
- Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development
- --
- Jeffrey V. Poulton
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 3.22M
- Dr. Akshay K. Vaishnaw, M.D.,PhD
- Chief Innovation Officer
- 3.32M
- Amy W. Schulman
- Chairman of the Board
- 531.36K
- Michael W. Bonney
- Director
- 467.23K
- Dr. Margaret A. Hamburg, M.D.
- Independent Director
- 471.39K
- Dr. Elliott Sigal, M.D.,PhD
- Independent Director
- 470.11K
- Dr. Carolyn R. Bertozzi, PhD
- Independent Director
- 668.94K
- Peter N. Kellogg
- Independent Director
- 658.72K
- Dr. Dennis A. Ausiello, M.D.
- Independent Director
- 477.21K
- Dr. Olivier Raymond Brandicourt, M.D.
- Independent Director
- 480.96K
- Dr. Phillip A. Sharp,PhD
- Independent Director
- 502.21K
- Colleen F. Reitan
- Independent Director
- 489.15K
- David E.I. Pyott, M.B.A.,M.D.
- Independent Director
- 477.21K
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!